Neuropeptide Y: a potential theranostic biomarker for diabetic peripheral neuropathy in patients with type-2 diabetes

Background: Diabetic peripheral neuropathy (DPN), the most common microvascular complication of type-2 diabetes mellitus (T2DM), results in nontraumatic lower-limb amputations. When DPN is not detected early, disease progression is irreversible. Thus, biomarkers for diagnosing DPN are needed. Method...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Noo Ree Cho, Yeuni Yu, Chang-Kyu Oh, Dai Sik Ko, Kyungjae Myung, Yoonsung Lee, Hee Sam Na, Yun Hak Kim
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/0a3da1dc74b347fc96d228c08c8d0645
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0a3da1dc74b347fc96d228c08c8d0645
record_format	dspace
spelling	oai:doaj.org-article:0a3da1dc74b347fc96d228c08c8d06452021-12-01T07:33:19ZNeuropeptide Y: a potential theranostic biomarker for diabetic peripheral neuropathy in patients with type-2 diabetes2040-623110.1177/20406223211041936https://doaj.org/article/0a3da1dc74b347fc96d228c08c8d06452021-09-01T00:00:00Zhttps://doi.org/10.1177/20406223211041936https://doaj.org/toc/2040-6231Background: Diabetic peripheral neuropathy (DPN), the most common microvascular complication of type-2 diabetes mellitus (T2DM), results in nontraumatic lower-limb amputations. When DPN is not detected early, disease progression is irreversible. Thus, biomarkers for diagnosing DPN are needed. Methods: We analyzed three data sets of T2DM DPN: two for mouse models (GSE70852 and GSE34889) and one for a human model (GSE24290). We found common differentially expressed genes (DEGs) in the two mouse data sets and validated them in the human data set. To identify the phenotypic function of the DEGs, we overexpressed them in zebrafish embryos. Clinical information and serum samples of T2DM patients with and without DPN were obtained from the Korea Biobank Network. To assess the plausibility of DEGs as biomarkers of DPN, we performed an enzyme-linked immunosorbent assay. Results: Among the DEGs, only NPY and SLPI were validated in the human data set. As npy is conserved in zebrafish, its mRNA was injected into zebrafish embryos, and it was observed that the branches of the central nervous system became thicker and the number of dendritic branches increased. Baseline characteristics between T2DM patients with and without DPN did not differ, except for the sex ratio. The mean serum NPY level was higher in T2DM patients with DPN than in those without DPN ( p = 0.0328), whereas serum SLPI levels did not differ ( p = 0.9651). Conclusion: In the pathogenesis of DPN, NPY may play a protective role in the peripheral nervous system and may be useful as a biomarker for detecting T2DM DPN.Noo Ree ChoYeuni YuChang-Kyu OhDai Sik KoKyungjae MyungYoonsung LeeHee Sam NaYun Hak KimSAGE PublishingarticleTherapeutics. PharmacologyRM1-950ENTherapeutic Advances in Chronic Disease, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950
spellingShingle	Therapeutics. Pharmacology RM1-950 Noo Ree Cho Yeuni Yu Chang-Kyu Oh Dai Sik Ko Kyungjae Myung Yoonsung Lee Hee Sam Na Yun Hak Kim Neuropeptide Y: a potential theranostic biomarker for diabetic peripheral neuropathy in patients with type-2 diabetes
description	Background: Diabetic peripheral neuropathy (DPN), the most common microvascular complication of type-2 diabetes mellitus (T2DM), results in nontraumatic lower-limb amputations. When DPN is not detected early, disease progression is irreversible. Thus, biomarkers for diagnosing DPN are needed. Methods: We analyzed three data sets of T2DM DPN: two for mouse models (GSE70852 and GSE34889) and one for a human model (GSE24290). We found common differentially expressed genes (DEGs) in the two mouse data sets and validated them in the human data set. To identify the phenotypic function of the DEGs, we overexpressed them in zebrafish embryos. Clinical information and serum samples of T2DM patients with and without DPN were obtained from the Korea Biobank Network. To assess the plausibility of DEGs as biomarkers of DPN, we performed an enzyme-linked immunosorbent assay. Results: Among the DEGs, only NPY and SLPI were validated in the human data set. As npy is conserved in zebrafish, its mRNA was injected into zebrafish embryos, and it was observed that the branches of the central nervous system became thicker and the number of dendritic branches increased. Baseline characteristics between T2DM patients with and without DPN did not differ, except for the sex ratio. The mean serum NPY level was higher in T2DM patients with DPN than in those without DPN ( p = 0.0328), whereas serum SLPI levels did not differ ( p = 0.9651). Conclusion: In the pathogenesis of DPN, NPY may play a protective role in the peripheral nervous system and may be useful as a biomarker for detecting T2DM DPN.
format	article
author	Noo Ree Cho Yeuni Yu Chang-Kyu Oh Dai Sik Ko Kyungjae Myung Yoonsung Lee Hee Sam Na Yun Hak Kim
author_facet	Noo Ree Cho Yeuni Yu Chang-Kyu Oh Dai Sik Ko Kyungjae Myung Yoonsung Lee Hee Sam Na Yun Hak Kim
author_sort	Noo Ree Cho
title	Neuropeptide Y: a potential theranostic biomarker for diabetic peripheral neuropathy in patients with type-2 diabetes
title_short	Neuropeptide Y: a potential theranostic biomarker for diabetic peripheral neuropathy in patients with type-2 diabetes
title_full	Neuropeptide Y: a potential theranostic biomarker for diabetic peripheral neuropathy in patients with type-2 diabetes
title_fullStr	Neuropeptide Y: a potential theranostic biomarker for diabetic peripheral neuropathy in patients with type-2 diabetes
title_full_unstemmed	Neuropeptide Y: a potential theranostic biomarker for diabetic peripheral neuropathy in patients with type-2 diabetes
title_sort	neuropeptide y: a potential theranostic biomarker for diabetic peripheral neuropathy in patients with type-2 diabetes
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/0a3da1dc74b347fc96d228c08c8d0645
work_keys_str_mv	AT nooreecho neuropeptideyapotentialtheranosticbiomarkerfordiabeticperipheralneuropathyinpatientswithtype2diabetes AT yeuniyu neuropeptideyapotentialtheranosticbiomarkerfordiabeticperipheralneuropathyinpatientswithtype2diabetes AT changkyuoh neuropeptideyapotentialtheranosticbiomarkerfordiabeticperipheralneuropathyinpatientswithtype2diabetes AT daisikko neuropeptideyapotentialtheranosticbiomarkerfordiabeticperipheralneuropathyinpatientswithtype2diabetes AT kyungjaemyung neuropeptideyapotentialtheranosticbiomarkerfordiabeticperipheralneuropathyinpatientswithtype2diabetes AT yoonsunglee neuropeptideyapotentialtheranosticbiomarkerfordiabeticperipheralneuropathyinpatientswithtype2diabetes AT heesamna neuropeptideyapotentialtheranosticbiomarkerfordiabeticperipheralneuropathyinpatientswithtype2diabetes AT yunhakkim neuropeptideyapotentialtheranosticbiomarkerfordiabeticperipheralneuropathyinpatientswithtype2diabetes
_version_	1718405395935920128

Neuropeptide Y: a potential theranostic biomarker for diabetic peripheral neuropathy in patients with type-2 diabetes

Ejemplares similares